Released Nov 7, 2023, after the close
10-Q filed Nov 7, 2023, 38 days after period end · 0000950170-23-060385
Q3 2023 · 10-Q
Revenue$25.37M$25.37M −1.1% vs Q3 2022−8.3% vs Q2 2023
Net Income-$21.00M-$21.00M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.27-$0.27 N/M vs Q3 2022N/M vs Q2 2023
Gross Profit$11,154,000+21.0%
Operating Income-$21,172,000N/M
Operating Cash Flowderived-$11,412,000N/M
Free Cash Flowderived-$12,317,000N/M
Margins · derived
Gross margin44.0%+8.0 pt vs Q3 2022
Operating margin-83.5%+29.7 pt vs Q3 2022
Net margin-82.8%+32.0 pt vs Q3 2022
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $25.37M | $25.65M | $28.50M | $39.86M |
| Net Income | -$21.00M | -$29.43M | -$13.84M | -$6.00M |
| EPS Diluted | -$0.27 | -$0.37 | -$0.18 | -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR